330350 — Withus Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Withus Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 June 30th	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	52,393	57,419	64,680	80,119	102,722
Cost of Revenue
Gross Profit	32,967	33,525	38,335	48,638	65,554
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	42,658	52,533	59,803	72,210	97,266
Operating Profit	9,735	4,886	4,878	7,909	5,456
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10,036	5,240	4,158	9,141	5,139
Provision for Income Taxes
Net Income After Taxes	8,039	4,264	2,479	7,959	4,785
Net Income Before Extraordinary Items
Net Income	8,039	4,264	2,479	7,959	4,785
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,039	4,264	2,479	7,959	4,785
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	691	347	187	603	377
Dividends per Share